COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors

COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors

Abstract In studies evaluating the efficacy of anti-programmed cell death 1/ligand 1 immune checkpoint inhibitors (anti-PD-(L)1) among patients with non-small cell lung cancer (NSCLC), smokers tend to have better clinical outcomes than non-smokers. However, it is unclear whether NSCLC patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Augustin Boudoussier, Iban Larrouture, Pauline Henrot, Rémi Veillon, Claire Bardel, Camille Chautemps, Charline Caumont, Pierre Schilfarth, Michael Duruisseaux, Maeva Zysman
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Chronic obstructive pulmonary disease
Non-small cell lung cancer
Immune checkpoint inhibitors
Progression-free survival
Overall survival
Online Access:https://doi.org/10.1038/s41598-025-02251-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-02251-0

Similar Items